Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

264.06 

-4.40 -1.6%

as of Oct 26 '20

52 Week Range:

155.17 286.68


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. Bio-Techne Corporation has partnership with Kantaro Biosciences to develop and scale production of COVID-19 serology test. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Equity (BVPS) 13.55
15.78
17.50
19.53
21.00
22.07
22.90
24.30
28.14
30.22
33.58
growth rate 16.5% 10.9% 11.6% 7.5% 5.1% 3.8% 6.1% 15.8% 7.4% 11.1%
Earnings BIT 156.45
164.98
162.20
160.66
168.13
158.50
158.79
149.41
163.44
152.74
growth rate 5.5% -1.7% -1.0% 4.7% -5.7% 0.2% -5.9% 9.4% -6.6%
Avg.PE 19.53
27.62
24.45
22.62
30.86
31.92
38.17
58.21
54.31
65.59
56.63
growth rate 41.4% -11.5% -7.5% 36.4% 3.4% 19.6% 52.5% -6.7% 20.8% -13.7%
ROA 22.16
19.76
16.80
15.03
13.53
11.19
9.53
5.66
8.00
5.52
11.71
growth rate -10.8% -15.0% -10.5% -10.0% -17.3% -14.8% -40.6% 41.3% -31.0% 112.1%
ROE 22.91
20.65
17.82
15.94
14.48
13.12
12.10
8.32
12.43
8.55
17.99
growth rate -9.9% -13.7% -10.6% -9.2% -9.4% -7.8% -31.2% 49.4% -31.2% 110.4%
ROIC 22.27
20.18
17.53
15.68
14.00
12.51
11.12
7.14
10.02
7.36
14.03
growth rate -9.4% -13.1% -10.6% -10.7% -10.6% -11.1% -35.8% 40.3% -26.6% 90.6%
Cur. Ratio 11.81
12.67
9.69
12.76
17.79
6.24
4.69
2.57
5.01
4.05
4.88
growth rate 7.3% -23.5% 31.7% 39.4% -64.9% -24.8% -45.2% 94.9% -19.2% 20.5%
Quick Ratio 10.16
9.82
8.58
11.63
15.85
4.55
3.49
2.03
3.80
2.98
3.69
growth rate -3.4% -12.6% 35.6% 36.3% -71.3% -23.3% -41.8% 87.2% -21.6% 23.8%
Leverage 1.03
1.05
1.07
1.05
1.08
1.26
1.28
1.64
1.48
1.62
1.46
growth rate 1.9% 1.9% -1.9% 2.9% 16.7% 1.6% 28.1% -9.8% 9.5% -9.9%
Balance Sheet Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Acct.Receivable 30.90
35.90
37.74
40.18
55.00
70.03
93.39
116.83
120.30
137.47
122.53
growth rate 16.2% 5.1% 6.5% 36.9% 27.3% 33.4% 25.1% 3.0% 14.3% -10.9%
Acct.Payable 35.75
32.08
9.65
13.44
20.65
16.86
18.45
16.21
23.09
growth rate -10.3% -69.9% 39.3% 53.6% -18.4% 9.5% -12.2% 42.4%
Cur.Assets 201.00
230.40
346.51
409.52
469.41
248.28
253.89
348.03
398.37
412.61
520.92
growth rate 14.6% 50.4% 18.2% 14.6% -47.1% 2.3% 37.1% 14.5% 3.6% 26.3%
Total Assets 518.80
617.70
719.32
778.10
862.49
1,063.36
1,129.58
1,558.22
1,593.20
1,884.41
2,027.59
growth rate 19.1% 16.5% 8.2% 10.9% 23.3% 6.2% 38.0% 2.3% 18.3% 7.6%
Cash 94.10
77.60
116.68
163.79
318.57
54.53
64.24
91.61
121.99
100.89
146.63
growth rate -17.5% 50.4% 40.4% 94.5% -82.9% 17.8% 42.6% 33.2% -17.3% 45.3%
Inventory 13.70
44.90
38.28
34.88
38.85
49.58
57.10
60.15
85.65
91.05
103.15
growth rate 227.7% -14.8% -8.9% 11.4% 27.6% 15.2% 5.3% 42.4% 6.3% 13.3%
Cur.Liabilities 17.00
18.20
35.75
32.08
26.39
39.77
54.15
135.52
79.51
101.99
106.67
growth rate 7.1% 96.4% -10.3% -17.7% 50.7% 36.2% 150.3% -41.3% 28.3% 4.6%
Liabilities 17.00
31.50
44.88
40.56
67.23
216.43
250.30
608.59
514.14
718.82
growth rate 85.3% 42.5% -9.6% 65.8% 221.9% 15.7% 143.1% -15.5% 39.8%
LT Debt 0.00
0.00
0.00
0.00
7.00
73.00
91.50
343.77
339.00
505.12
growth rate 943.3% 25.3% 275.7% -1.4% 49.0%
Equity 501.80
586.10
674.44
737.54
795.27
846.94
879.28
949.63
1,079.06
1,165.59
1,381.19
growth rate 16.8% 15.1% 9.4% 7.8% 6.5% 3.8% 8.0% 13.6% 8.0% 18.5%
Common Shares 37.00
37.00
37.00
36.00
37.00
37.00
37.00
38.00
38.00
39.00
39.00
growth rate 0.0% 0.0% -2.7% 2.8% 0.0% 0.0% 2.7% 0.0% 2.6% 0.0%
Cash Flow Statement Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Capital Expenditures 4.60
3.60
6.02
22.45
13.82
19.91
16.90
15.18
20.93
25.41
growth rate -21.7% 67.1% 273.2% -38.5% 44.0% -15.1% -10.2% 37.9% 21.4%
Cash Dividends 38.40
39.70
41.02
43.46
45.39
47.11
47.61
47.33
47.97
48.36
growth rate 3.4% 3.3% 6.0% 4.4% 3.8% 1.1% -0.6% 1.4% 0.8%
Cash From OA 111.30
127.20
126.75
123.56
136.76
139.36
144.16
143.72
170.37
181.62
205.22
growth rate 14.3% -0.4% -2.5% 10.7% 1.9% 3.4% -0.3% 18.5% 6.6% 13.0%
FCF per Share 2.85
3.32
3.18
3.06
3.02
3.37
3.32
3.11
3.57
4.42
4.33
growth rate 16.5% -4.2% -3.8% -1.3% 11.6% -1.5% -6.3% 14.8% 23.8% -2.0%
Sale Purchase of Stock -23.66
-1.29
8.33
9.73
5.46
5.26
growth rate 0.0% 100.0% 16.9% -43.9% -3.7%
FCF 107.00
124.00
121.00
101.00
123.00
119.00
127.00
128.00
149.00
156.00
153.00
growth rate 15.9% -2.4% -16.5% 21.8% -3.3% 6.7% 0.8% 16.4% 4.7% -1.9%
Income Statement Jun '10 Jun '11 Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20
Sales 269.00
290.00
314.56
310.58
357.76
452.25
499.02
563.00
642.99
714.01
738.69
growth rate 7.8% 8.5% -1.3% 15.2% 26.4% 10.3% 12.8% 14.2% 11.0% 3.5%
Op.Income 156.30
163.10
112.33
112.56
168.13
158.50
158.79
149.41
163.44
152.74
growth rate 4.4% -31.1% 0.2% 49.4% -5.7% 0.2% -5.9% 9.4% -6.6%
IBT 156.40
165.00
162.20
160.66
161.39
154.16
147.48
111.96
125.95
112.02
276.48
growth rate 5.5% -1.7% -1.0% 0.5% -4.5% -4.3% -24.1% 12.5% -11.1% 146.8%
Net Income 109.80
112.30
112.33
112.56
110.95
107.74
104.48
76.09
126.15
96.07
229.30
growth rate 2.3% 0.0% 0.2% -1.4% -2.9% -3.0% -27.2% 65.8% -23.8% 138.7%
EPS 2.94
3.02
3.04
3.05
3.00
2.89
2.80
2.03
3.31
2.47
5.82
growth rate 2.7% 0.7% 0.3% -1.6% -3.7% -3.1% -27.5% 63.1% -25.4% 135.6%
Gross Profit 214.10
224.90
235.80
231.11
258.89
314.24
342.09
377.58
434.60
477.23
growth rate 5.0% 4.9% -2.0% 12.0% 21.4% 8.9% 10.4% 15.1% 9.8%
R&D 25.10
26.00
27.91
29.26
30.95
40.85
45.19
53.51
55.33
62.41
65.19
growth rate 3.6% 7.4% 4.8% 5.8% 32.0% 10.6% 18.4% 3.4% 12.8% 4.5%

Quarterly Statements

Item Name Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 44.63
43.51
35.34
36.11
47.47
growth rate -2.5% -18.8% 2.2% 31.5%
Balance Sheet Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 133.93
137.47
122.72
111.75
117.45
growth rate 2.6% -10.7% -8.9% 5.1%
Acct.Payable 14.90
16.21
14.11
19.09
19.74
growth rate 8.8% -13.0% 35.4% 3.4%
Cur.Assets 423.43
412.61
391.95
465.07
491.93
growth rate -2.6% -5.0% 18.7% 5.8%
Total Assets 1,872.62
1,884.41
1,925.03
1,998.42
1,999.02
growth rate 0.6% 2.2% 3.8% 0.0%
Cash 95.56
100.89
99.89
110.29
156.22
growth rate 5.6% -1.0% 10.4% 41.6%
Inventory 93.84
91.05
90.86
95.35
99.67
growth rate -3.0% -0.2% 5.0% 4.5%
Cur.Liabilities 98.05
101.99
88.27
104.95
104.99
growth rate 4.0% -13.5% 18.9% 0.0%
Liabilities 726.35
718.82
750.80
675.07
707.75
growth rate -1.0% 4.5% -10.1% 4.8%
LT Debt 517.33
505.12
486.67
381.73
426.07
growth rate -2.4% -3.7% -21.6% 11.6%
Equity 1,146.27
1,165.59
1,174.22
1,323.35
1,291.27
growth rate 1.7% 0.7% 12.7% -2.4%
Common Shares 0.38
0.38
0.38
0.38
0.38
growth rate 0.3% 0.5% 0.5% -0.5%
Cash Flow Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 4.93
11.69
10.53
14.56
9.28
growth rate 137.4% -10.0% 38.4% -36.3%
Cash Dividends 12.09
12.13
12.17
12.20
12.28
growth rate 0.3% 0.4% 0.2% 0.7%
Cash From OA 39.66
55.95
40.54
70.42
49.47
growth rate 41.1% -27.5% 73.7% -29.8%
Sale Purchase of Stock
growth rate
FCF 34.74
44.25
30.01
55.85
40.19
growth rate 27.4% -32.2% 86.1% -28.1%
Income Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Sales 184.86
191.67
183.24
184.93
194.68
growth rate 3.7% -4.4% 0.9% 5.3%
Op.Income 44.63
43.51
35.34
36.11
47.47
growth rate -2.5% -18.8% 2.2% 31.5%
IBT 49.88
22.79
17.81
150.33
46.82
growth rate -54.3% -21.9% 744.2% -68.9%
Net Income 44.65
16.46
14.40
119.62
36.43
growth rate -63.1% -12.5% 730.8% -69.5%
EPS
growth rate
Gross Profit 125.55
129.20
118.41
121.40
130.06
growth rate 2.9% -8.3% 2.5% 7.1%
R&D 15.55
16.26
16.08
16.38
15.95
growth rate 4.6% -1.1% 1.9% -2.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (75.69)

YOY Growth Grade:

C (52.13)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 56.63 55.52 42.35
EPS / Growth 8.1% 4.76 6.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.0% 8.6% 8.6%
Future PE 12.00 38.71 38.71
Future EPS 8.52 10.82 10.82
Value Price
MOS %
25.26
-90.4%
103.55
-60.8%
103.55
-60.8%
MOS Price 12.63 51.77 51.77
IRT 24.39 20.46 20.46

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.